Abstract 78P
Background
Detecting oncogenic gene fusions that can be effectively targeted in a tumor type agnostic manner have been shown to transform patient care. Unfortunately, however, patients in certain community settings may only be tested for NTRK fusions following a positive IHC screen result. Here we compared the gap between panTRK IHC testing and NGS fusion confirmation for NTRK or additional fusions.
Methods
8307 clinical samples across 33 tumor types were tested for RNA fusions using a CLIA grade hybrid capture RNA-seq based fusionome-like assay. De-identified results were analyzed for either the 19 actionable fusion genes (ALK, BRAF, FGFR1-4, MET, NOTCH1/2, NRG1, NTRK1-3, PDGFB, PDGFRA/B, RAF1, RET and ROS1) or only for NTRK fusions. Pan-NTRK IHC results on fusion positive patients were analyzed. Data was analyzed according to an IRB-approved protocol.
Results
When we analyzed the NGS results, we detected a targetable fusion in 5.1% (n=422) patients. Of those 104 had a NTRK1/2/3/ fusion (38/10/56). The additional 3.8% patients had other therapy candidate fusions: ALK (0.6%), BRAF 0.3%, FGFRs 0.9%, MET 0.4%, NOTCH2 0.2%, NRG1 0.2%, PDGFRA 0.1%, RAF1 0.2%, RET 0.5%, ROS1 0.2%, excluding NTRK positive cases. Only 2 patients were positive for an NTRK fusion and an additional actionable fusion. From a total of 221 patients with actionable fusions by NGS, IHC was positive on 70% (51/73) of the NTRK fusion positive patients. Moreover, NTRK expression by IHC was found on 91% of NTRK1 and 100% of NTRK2, but only on 44% of the NTRK3 positive cases by NGS. Conversely, only 54% of the pan-TRK IHC positive patients expressed a NTRK fusion transcript while 46% expressed other RNA fusions, primarily FGFRs (20 %) ALK (4%) and ROS1 (4%).
Conclusions
The data demonstrates that up to 4 -fold more patients could have a fusion matched therapy when testing for 19 druggable fusions as compared to testing only for NTRK fusions or following IHC testing. Pan NTRK IHC failed to detect half of NTRK3 fusions. The data suggests that simultaneous detection of several actionable fusions by NGS can increase the therapeutic options for cancer patients in community settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H. Husain: Financial Interests, Personal, Speaker, Consultant, Advisor: Neogenomics. N. Montgomery, R. Puentes, D. Lyle: Financial Interests, Personal, Full or part-time Employment: Neogenomics. F. Lopez-Diaz: Financial Interests, Personal, Full or part-time Employment: Neogenomics; Financial Interests, Personal, Stocks/Shares: Neogenomics. All other authors have declared no conflicts of interest.
Resources from the same session
31P - Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors
Presenter: Li Lin
Session: Poster session 07
32P - Patient derived circulating tumor cell clusters for personalized chemotherapy
Presenter: Prashant Kumar
Session: Poster session 07
Resources:
Abstract
33P - Anti-tumor effect of Debio 0432, a potent and selective USP1 inhibitor, in combination with PARP inhibitors
Presenter: Noémie Luong
Session: Poster session 07
34P - A novel gene family underlying cancer cell resilience
Presenter: David Amici
Session: Poster session 07
35P - The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates
Presenter: Jianhui Ma
Session: Poster session 07
36P - Branched-chain amino acids metabolism reprogramming in trastuzumab primary resistant HER2 positive breast cancer
Presenter: Yijia Hua
Session: Poster session 07
37P - A consensus gene set facilitates enrichment analysis of cancer hallmarks
Presenter: Otília Menyhart
Session: Poster session 07
38P - Feasibility of expanding tumor-infiltrating lymphocytes from cryopreserved tumor specimens after long-term storage
Presenter: Daria Kuznetsova
Session: Poster session 07
39P - Search for rare copy number variants associated with hereditary breast cancer in Finnish case-control cohorts
Presenter: Timo Kumpula
Session: Poster session 07
40P - STOPIN: A new approach to solve the hematological toxicity of antibody-drug conjugates (ADC) with soft topoisomerase inhibitor
Presenter: Xinghai Wang
Session: Poster session 07